Yi Zheng has spent nearly two decades studying hematopoietic stem cellsthe white blood cells that power the immune systemand he's just announced a breakthrough that could " revolutionize immune system recovery after cancer therapies, enhance the efficacy of therapeutic agents, increase transplantation success rates, and offer comprehensive therapy for individuals with compromised blood systems," says the director of the Cancer and Blood Diseases Institute at the Cincinnati Children's Hospital.
His company, Mogling Bio, has entered into an exclusive agreement with the hospital to develop inhibitors to open up the bone marrow niche that allows stem cells to enter the blood stream and "rejuvenate aged hematopoietic stem cells," per a press release.
"By enhancing the body's access to revitalized stem cells, this innovation has the potential to revolutionize immune system recovery after cancer therapies, enhance the efficacy of therapeutic agents, increase transplantation success rates, and offer comprehensive therapy for individuals with compromised blood systems," says Mogling's CEO.
CASIN, a naturally occurring CDC42 inhibitor, "has shown astonishing preclinical results," Zheng says.
"With its ability to revolutionize blood and immune system recovery, amplify the effectiveness of therapeutic agents, increase success, and provide comprehensive therapy for individuals with compromised immune systems, this breakthrough has the potential to transform many
A customized collection of grant news from foundations and the federal government from around the Web.
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.